Skip to main content
Premium Trial:

Request an Annual Quote

Robert Millman, Elizabeth Stoner

Premium
Life science-investment firm MPM Capital said last week that Robert Millman and Elizabeth Stoner have joined as executive partners in MPM’s Boston office.
 
Millman was most recently chief IP counsel for Alnylam Pharmaceuticals. Prior to Alnylam, he served as the chief IP counsel at Infinity Pharmaceuticals for three years. From 1999 to 2002, Millman was chief IP counsel at Celera Genomics. Prior to that, he was patent counsel at Millennium Pharmaceuticals, an associate at Morrison and Foerster, and a patent agent at Sterne, Kessler Goldstein & Fox.
 
Millman received a JD from the Washington College of Law at American University, an MS in genetics from Washington State University, and a BS in biochemistry from the University of California, Riverside.
 
Stoner joins MPM after 22 years at Merck Research Laboratories, where she most recently served as senior vice president of global clinical development operations. Prior to Merck, she was an assistant professor of pediatrics at Cornell University Medical College.
 
Stoner received a BS in chemistry from Ottawa University, Kansas; an MS in chemistry from the State University of New York at Stony Brook, and an MD from Albert Einstein College of Medicine.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.